Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions

被引:6
|
作者
Trabelsi, Fethi [1 ]
Bartunek, Ales [2 ]
Vlavonou, Raphael [1 ]
Navratilova, Lucie [2 ]
Dube, Charlotte [1 ]
Tanguay, Mario [1 ]
Hauser, Tomas [2 ]
机构
[1] PharmaNet Canada Inc, Montreal, PQ H3X 2H9, Canada
[2] Zentiva, Prague, Czech Republic
关键词
bioequivalence; bioavailability; rosuvastatin; statins; hyperlipidemia;
D O I
10.5414/CP201687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Rosuvastatin, a synthetic lipid-lowering agent acts selectively by competitive inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A. It is indicated as an adjunct to diet in patients with hypercholesterolemia and mixed dyslipidemia. Objective: The purpose of this study was to demonstrate bioequivalence between a generic rosuvastatin 40 mg tablet (Zentiva, Prague, Czech Republic) and a reference product (Crestor, AstraZeneca, Luton, UK), under fasting conditions as required by the European Medicinal Agency. Methods: A single-oral 40 mg-dose, randomized, open-label, 2-way crossover design study was conducted in 42 healthy volunteers under fasting conditions. Rosuvastatin was administered following an overnight-fast in two occasions with a 14-day washout period in-between. Blood samples were collected in EDTA-K2 tubes prior to dosing and over a 96-hour period. Rosuvastatin was measured in plasma using an automated LC-MS/MS assay (range 81.02 - 40,512.00 pg/ml). Pharmacokinetics were performed using non-compartmental analyses approach to evaluate AUC(last), AUC(infinity) and C-max. ANOVA was performed on the ln-transformed data and the 90% Confidence Interval (CI) was determined. Bioequivalence will be concluded if the 90% CI falls within 80.00 - 125.00% for AUC(last) and Cmax. Safety and tolerability were also evaluated. Results: 39 volunteers completed the study and were considered for the pharmacokinetic and statistical analyses. Descriptive safety data analyses were performed on all subjects. All pharmacokinetic parameters met the acceptance criteria as the 90% CI were within 80.00 125.00%. Both formulations were well tolerated and no serious adverse events were reported. Conclusion: This study showed that the test and reference products met the regulatory criteria for bioequivalence following a 40 mg oral dose under fasting conditions.
引用
收藏
页码:741 / 750
页数:10
相关论文
共 50 条
  • [1] Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study
    Almeida, Susana
    Pedroso, Pedro
    Filipe, Augusto
    Pinho, Catarina
    Neves, Rita
    Jimenez, Cintia
    Sicard, Eric
    Lefebvre, Marc
    [J]. ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2011, 61 (03): : 153 - 159
  • [2] Single-dose, 2-way crossover, bioequivalence study of dexmethylphenidate with and without food in healthy subjects.
    Teo, S
    Scheffler, M
    Stirling, D
    Thomas, S
    Khetani, V
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P36 - P36
  • [3] Single-dose, Two-way Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects
    Patel, Shashank
    Chauhan, Vijay
    Mandal, Jayanta
    Shah, Samir
    Patel, Keyur
    Saptarshi, Dipak
    Maheshwari, Kirti
    Jha, Pankaj Kumar
    Kale, Prashant
    Patel, Kamlesh
    Mathew, Philip
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (03) : 378 - 390
  • [4] Bioequivalence study of two formulations of afatinib dimaleate tablets in healthy subjects under fasting conditions: A randomized, open-label, single-dose, crossover trial
    Liu, Yanping
    Lue, Lang
    Xu, Man
    Tao, Juanmin
    Ning, Yuping
    Shi, Yan
    Dong, Yanfen
    Cao, Qingqing
    Ma, Jun
    Qiu, Yan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (10) : 479 - 485
  • [5] Pharmacokinetics and Bioequivalence of Two Formulations of Rosuvastatin Following Single-dose Administration in Healthy Chinese Subjects Under Fasted and Fed Conditions
    Zhu, Ke-Wei
    Wang, Gan-Mi
    Li, Chu-Yuan
    Liu, Ju-Yan
    Huang, Jin-Ying
    Wu, Jia-Rong
    Song, Wen-Jie
    Deng, Jun
    Wang, Jian-Song
    Qin, Fei
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (08): : 987 - 996
  • [6] Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions
    Filipe, A.
    Almeida, S.
    Franco Spinola, A. C.
    Neves, R.
    Tanguay, M.
    Jimenez, C.
    Shink, E.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (03) : 187 - 194
  • [7] Bioequivalence of Two Formulations of Gliclazide in a Randomized Crossover Study in Healthy Caucasian Subjects Under Fasting Conditions
    Pop, Diana Ioana
    Oroian, Monica
    Bhardwaj, Sandeep
    Marcovici, Adriana
    Khuroo, Arshad
    Kochhar, Ravi
    Vlase, Laurian
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 16 - 21
  • [8] Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions
    Almeida, Susana
    Filipe, Augusto
    Neves, Rita
    Desjardins, Isabelle
    Shink, Eric
    Castillo, Araceli
    [J]. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2010, 60 (03): : 116 - 123
  • [9] Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions
    Trabelsi, Fethi
    Gharavi, Negar
    Kalovidouris, Magdalene
    Nikolaidou, Martha
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (09) : 732 - 742
  • [10] A Single-Dose, Crossover-Design Bioequivalence Study Comparing Two Nicotine Gum Formulations in Healthy Subjects
    Du, Daniel
    [J]. ADVANCES IN THERAPY, 2018, 35 (08) : 1169 - 1180